📄 medicine

Impact of imperatorin and isoimperatorin on the pharmacokinetics of abemaciclib both in vivo and in vitro

This study demonstrates that co-administration of imperatorin or isoimperatorin significantly alters the pharmacokinetics of the breast cancer drug abemaciclib in rats by inhibiting its metabolism, likely through competition for CYP3A4 binding, suggesting a need for clinical caution when combining these agents.

Original authors: Chengfeng Wang, Jianfeng Wang, Zebei Lu, Yu Wang, Abdullah Al Mamun, Md Siddiqul Islam, Shuanghu Wang, Yunfang Zhou, Minzhi Xu

Published 2026-07-07

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Chengfeng Wang, Jianfeng Wang, Zebei Lu, Yu Wang, Abdullah Al Mamun, Md Siddiqul Islam, Shuanghu Wang, Yunfang Zhou, Minzhi Xu

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Picture: A Traffic Jam in the Liver

Imagine your body is a busy city, and your liver is the main traffic control center. Its job is to process everything you eat or swallow, breaking down medicines so they can do their job and then clear them out of your system.

In this study, scientists looked at what happens when you take a specific cancer drug called Abemaciclib (the "delivery truck") at the same time as two natural compounds found in certain herbs: Imperatorin and Isoimperatorin (the "roadblocks").

The researchers wanted to know: Do these natural roadblocks slow down the delivery truck too much, causing a traffic jam that keeps the medicine in the body longer than intended?

The Cast of Characters

Abemaciclib: A powerful medicine used to treat breast cancer. It needs to be broken down by a specific machine in the liver called CYP3A4 (think of this as the "garbage disposal unit" or the "scissors" that cuts the drug up so it can leave the body).
Imperatorin & Isoimperatorin: Natural chemicals found in plants like Angelica and Fennel. They are often used in traditional medicine for various health issues, including fighting tumors.
The Rats: The scientists used rats as test subjects to see how these chemicals interact inside a living body.

The Experiment: Three Groups of Rats

The researchers divided 18 rats into three groups to see how the "traffic" changed:

Group 1 (Control): Got only the cancer drug (Abemaciclib).
Group 2: Got the cancer drug + Imperatorin.
Group 3: Got the cancer drug + Isoimperatorin.

They then measured how much of the drug was in the rats' blood over time.

What They Found: The Traffic Jam

The results showed that when the rats took the natural compounds (Imperatorin or Isoimperatorin) along with the cancer drug, the drug stayed in their bodies much longer and at higher levels than in the control group.

The "AUC" (Area Under the Curve): Imagine this as the total amount of "traffic" on the road over time. In the groups with the natural compounds, this number went up significantly. It means the drug was hanging around in the bloodstream longer.
The "Cmax" (Peak Speed): This is the highest level of drug in the blood. This also went up.
The "CLz/F" (Clearance): This is how fast the liver cleans the drug out. This number went down, meaning the liver was struggling to clear the drug because it was busy dealing with the natural compounds instead.

In simple terms: The natural compounds acted like a clog in the drain. The liver couldn't process the cancer drug as fast as usual, so the drug built up in the system.

The "Why": The Molecular Lock and Key

To understand why this happened, the scientists looked at the microscopic level using computer simulations (molecular docking) and lab tests.

The Lock: The liver enzyme (CYP3A4) is like a lock that usually opens to let the cancer drug pass through.
The Keys: Both the cancer drug and the natural compounds (Imperatorin/Isoimperatorin) look very similar. They are all trying to fit into the same lock.
The Result: The natural compounds are very good at grabbing onto the lock. They sit there and block the cancer drug from getting processed. The computer models showed that the natural compounds bind to the enzyme almost as tightly as the cancer drug does, effectively "parking" themselves in the enzyme's spot and preventing the drug from being broken down.

The study found that these natural compounds are moderate inhibitors, meaning they don't completely stop the engine, but they definitely slow it down enough to cause a significant change.

The Conclusion

The researchers concluded that if a patient is taking Abemaciclib for breast cancer, and they also take herbs containing Imperatorin or Isoimperatorin, the levels of the cancer drug in their body could rise unexpectedly.

The Takeaway: Just because something is "natural" doesn't mean it's safe to mix with prescription drugs. In this specific case, mixing these two types of substances creates a chemical traffic jam that changes how the body handles the cancer medicine. The study suggests that doctors should be aware of this interaction if they ever prescribe these herbs alongside this specific cancer drug.

Technical Summary: Impact of Imperatorin and Isoimperatorin on the Pharmacokinetics of Abemaciclib

Problem Statement
Abemaciclib is a clinically approved CDK4/6 inhibitor used for treating hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Its metabolism is primarily mediated by the cytochrome P450 3A4 (CYP3A4) enzyme. Concurrently, imperatorin (IMP) and isoimperatorin (IIMP) are natural furanocoumarins found in various medicinal herbs (e.g., Angelica dahurica, Foeniculum vulgare) that possess pharmacological activities including anti-tumor effects. While previous studies have established that furanocoumarins can inhibit CYP450 enzymes, the specific drug-drug interactions (DDIs) between IMP/IIMP and abemaciclib remain poorly explored. Given that these compounds may be co-administered in clinical settings, there is a critical need to evaluate whether IMP and IIMP alter the pharmacokinetics (PK) of abemaciclib, potentially leading to toxicity or therapeutic failure.

Methodology
The study employed a comprehensive approach combining in vivo animal models, in vitro enzymatic assays, and computational molecular docking to assess the interaction.

In Vivo Pharmacokinetics: Eighteen male Sprague-Dawley (SD) rats were randomized into three groups: a control group, an IMP-treated group (50 mg/kg/day for 14 days), and an IIMP-treated group (50 mg/kg/day for 14 days). All groups received a single oral dose of abemaciclib (10 mg/kg) 30 minutes after the final IMP or IIMP administration. Plasma samples were collected over 72 hours and analyzed using a validated UPLC-MS/MS method to determine abemaciclib concentrations. Pharmacokinetic parameters ( $AUC_{0-\infty}$ , $C_{max}$ , $CL_z/F$ , $t_{1/2}$ ) were calculated using DAS software.
In Vitro Metabolism: Rat liver microsomes (RLMs) were prepared to simulate hepatic metabolism. The study determined the half-maximal inhibitory concentration ( $IC_{50}$ ) of IMP and IIMP against abemaciclib metabolism. Furthermore, enzyme kinetic studies were conducted using various substrate and inhibitor concentrations to generate Lineweaver-Burk and Dixon plots, allowing for the calculation of inhibition constants ( $K_i$ and $\alpha K_i$ ) to identify the inhibition mechanism.
Molecular Docking: The inhibitory mechanism was further investigated using AutoDock Vina and AutoDock 4.2. The 3D crystal structure of CYP3A4 (PDB ID: 2J0D) was docked with IMP, IIMP, and abemaciclib to analyze binding affinities and interactions with specific amino acid residues.

Key Results

Pharmacokinetic Alterations: Co-administration of IMP or IIMP significantly altered the PK profile of abemaciclib in rats compared to the control group.
- Exposure: Both groups exhibited significantly higher $AUC_{0-\infty}$ and $C_{max}$ values. The IMP group showed a 1.70-fold increase in $AUC_{0-\infty}$ and a 1.59-fold increase in $C_{max}$ . The IIMP group showed a 1.58-fold increase in $AUC_{0-\infty}$ and a 1.44-fold increase in $C_{max}$ .
- Clearance and Half-life: The apparent oral clearance ( $CL_z/F$ ) was significantly reduced (by approximately 42% in the IMP group and 38% in the IIMP group). The elimination half-life ( $t_{1/2}$ ) was prolonged in both treatment groups.
In Vitro Inhibition: IMP and IIMP demonstrated moderate inhibition of abemaciclib metabolism in RLMs, with $IC_{50}$ values of 6.79 µM and 6.56 µM, respectively. Kinetic analysis revealed that both compounds inhibit abemaciclib metabolism via a mixed inhibition mechanism.
Molecular Docking: Simulation results indicated that IMP, IIMP, and abemaciclib all exhibit strong binding capacities with CYP3A4. The minimum binding energies were calculated at -7.9 kcal/mol and -10.3 kcal/mol. Specifically, IMP and IIMP were found to form hydrogen bonds with the ALA-370 and ARG-105 amino acid residues within the CYP3A4 active site, suggesting a competitive or allosteric interference with the enzyme's ability to metabolize abemaciclib.

Significance and Claims
The authors conclude that imperatorin and isoimperatorin significantly impair the metabolism of abemaciclib both in vivo and in vitro by inhibiting CYP3A4 activity. This inhibition leads to increased systemic exposure and reduced clearance of abemaciclib, which could elevate the risk of adverse effects if these compounds are co-administered without dosage adjustment.

The paper claims that these findings provide a scientific basis for considering potential drug-drug interactions in clinical practice. Specifically, the authors suggest that when abemaciclib is combined with herbal medicines containing IMP or IIMP, clinicians should consider adjusting the dosage to mitigate the risk of toxicity. The study highlights the necessity of evaluating natural compounds like furanocoumarins in the context of modern targeted cancer therapies to ensure patient safety.